Efficacy and Safety of Pantoprazole Delayed‐release Granules for Oral Suspension in a Placebo‐controlled Treatment‐withdrawal Study in Infants 1–11 Months Old With Symptomatic GERD
Harland S. Winter(Harvard University), Gail M. Comer(Pfizer (United States)), Jarosław Kierkuś(Children's Memorial Health Institute), Michelle Hinz(Pfizer (United States)), Suleman H Mahomedy, Philip Kum‐Nji(Virginia Commonwealth University), Mary K. Maguire(Pfizer (United States)), Huihua Li(Dalian Medical University)
Cited by 74
Related Papers
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k
Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children
|Gastroenterology|2006|872
Evaluation, Diagnosis, and Treatment of Gastrointestinal Disorders in Individuals With ASDs: A Consensus Report
|PEDIATRICS|2010|870
Children with early-onset inflammatory bowel disease (IBD): Analysis of a pediatric IBD consortium registry
|The Journal of Pediatrics|2005|571
Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis
|Clinical Gastroenterology and Hepatology|2011|282